Results of 503-Patient Clinical Study of AspenBio Pharma's AppyScore™ Blood Test Show 97% Negative Predictive Value for Absence of Acute Appendicitis in Children and Adolescents Presenting with Abdominal Pain
The results from AspenBio Pharma's (NASDAQ: APPY ) 503-patient pilot study of AppyScore™ will be presented from the podium the upcoming West Region meeting of the Society for Academic Emergency Medicine (SAEM) being held in Las Vegas, March 16-17.
AppyScore is a multi-marker blood-based test panel consisting of the company's patented MRP 8/14 biomarker and C-reactive protein, along with white blood cell count. AppyScore is designed to aid emergency physicians in the identification of children and adolescents at low risk when acute appendicitis is suspected due to abdominal pain. The AppyScore test is in development and not yet approved for use. Abdominal pain is the number-one reason for hospital emergency department visits, and appendectomy is the number-one reason for emergency abdominal surgery.
The pilot study included pediatric and adolescent patients ages 2-20 with symptoms suspicious for acute appendicitis who were enrolled at 11 hospital sites across the country. Results for the AppyScore test showed a negative predictive value of 97% and sensitivity of 96%.
"Evaluating children and adolescents for appendicitis is difficult, and strategies have been sought to improve the precision of the diagnosis,” said David Spiro, M.D., a clinical investigator in the AppyScore pilot study and a pediatric emergency medicine specialist at Oregon Health & Sciences University, Portland, Ore. “Development of a quick and reliable blood test will provide clinicians with a tool that can be used to help reduce unnecessary exposure to ionizing radiation.”
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.